Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA).

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...